<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554903</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-205</org_study_id>
    <nct_id>NCT02554903</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation</brief_title>
  <acronym>SOPRANO</acronym>
  <official_title>A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY OBJECTIVES Primary objective To evaluate the effect of macitentan 10 mg on pulmonary
      vascular resistance (PVR) as compared to placebo in subjects with pulmonary hypertension (PH)
      after left ventricular assist device (LVAD) implantation.

      Secondary objectives To evaluate the effect of macitentan 10 mg as compared to placebo on
      cardio-pulmonary hemodynamics and disease severity in subjects with PH after LVAD
      implantation.

      To evaluate the safety and tolerability of macitentan 10 mg in subjects with PH after LVAD
      implantation.

      Exploratory objectives To explore the potential effect of macitentan 10 mg as compared to
      placebo on right ventricular function in subjects with PH after LVAD implantation.

      To explore the potential effect of macitentan 10 mg as compared to placebo on selected
      clinical events in subjects with PH after LVAD implantation.

      To explore the potential effect of macitentan 10 mg as compared to placebo on renal function
      as measured by glomerular filtration rate (GFR) in subjects with PH after LVAD implantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Vascular Resistance (PVR) ratio of Week 12 to Baseline.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in mean right atrial pressure (mPAP)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in mean pulmonary arterial pressure (mPAP)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in pulmonary arterial wedge pressure (PAWP)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in cardiac index (CI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in total pulmonary resistance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in mixed venous oxygen saturation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) from Baseline to Week 12.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in World Health Organization (WHO) functional class from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Macitentan 10 mg po</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan 10mg</intervention_name>
    <description>2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo</description>
    <arm_group_label>Macitentan 10 mg po</arm_group_label>
    <other_name>Active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo sugar pill</intervention_name>
    <description>2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo</description>
    <arm_group_label>Placebo sugar pill</arm_group_label>
    <other_name>placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Informed Consent prior to initiation of any study-mandated procedure.

          2. Males or females ≥ 18 years of age.

          3. Surgical implantation of LVAD within 90 days prior to Randomization.

          4. Hemodynamic evidence of PH on Baseline right heart catheterization (RHC) by the
             thermodilution method. Baseline RHC is defined as the last hemodynamic measurements
             after LVAD implantation and prior to the first dose of study treatment. PH is defined
             as:

               1. Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

               2. Pulmonary artery wedge pressure (PAWP) ≤ 18 mmHg and

               3. PVR &gt; 3 Wood units.

          5. Stabilization of the patient for 48 h prior to the Baseline RHC, defined as:

               1. No LVAD pump speed/flow rate changes and

               2. Stable dose of oral diuretics and

               3. No intravenous (i.v.) inotropes or vasopressors and

               4. Patient able to ambulate.

          6. A woman of childbearing potential is eligible only if she has:

               1. A negative serum pregnancy test result during the Screening period (Visit 1) and
                  Randomization (Visit 2) and

               2. Agreement to undertake monthly serum pregnancy tests during the study and up to
                  30 days after study treatment discontinuation and

               3. Agreement to use one of the methods of contraception / follow the contraception
                  scheme described in Section 4.5 from Screening and up to at least 30 days after
                  study treatment discontinuation.

          7. Patient must be randomized within 14 days of Baseline RHC.

        Exclusion Criteria:

          1. Documented severe obstructive lung disease defined as: forced expiratory volume in 1
             second / forced vital capacity (FEV1/FVC) &lt; 0.7 associated with FEV1 &lt; 50% of
             predicted value after bronchodilator administration.

          2. Documented moderate to severe restrictive lung disease defined as: total lung capacity
             &lt; 60% of predicted value.

          3. Documented pulmonary veno-occlusive disease.

          4. Patients undergoing dialysis.

          5. Hemoglobin &lt; 8.5 g/dL at Randomization.

          6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 × the upper
             limit of normal (ULN) at Randomization.

          7. Severe hepatic impairment, e.g., Child-Pugh Class C liver disease.

          8. Body weight &lt; 40 kg at Randomization.

          9. Doppler mean blood pressure &lt; 65 mmHg at Randomization.

         10. GFR &lt; 30 mL/min at Randomization.

         11. Pregnant, planning to become pregnant during the study period, or breastfeeding.

         12. Treatment with endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE5)
             inhibitors, i.v., subcutaneous (s.c.), or oral prostanoids, or guanylate cyclase
             stimulators within 7 days prior to Baseline RHC or study treatment initiation.

         13. Treatment with inhaled prostanoids (e.g., iloprost, epoprostenol) or nitric oxide
             within 24 h prior to Baseline RHC or study treatment initiation.

         14. Treatment with strong inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 28 days
             prior to study treatment initiation (e.g., carbamazepine, rifampicin, rifabutin,
             phenytoin and St. John's Wort).

         15. Treatment with strong inhibitors of CYP3A4 within 28 days prior to study treatment
             initiation (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin,
             telithromycin, nefazodone, ritonavir, saquinavir, boceprevir, telaprevir, iopinavir,
             fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, and
             idinavir).

         16. Treatment with another investigational drug (planned, or taken) within 28 days prior
             to study treatment initiation.

         17. Known hypersensitivity to ERAs, or to any of the study treatment excipients.

         18. Any condition that prevents compliance with the protocol or adherence to therapy.

         19. Known concomitant life-threatening disease with a life expectancy &lt; 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mona Selej, MD</last_name>
    <phone>650-624-6900</phone>
    <email>mselej@its.jnj.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Agron, PhD</last_name>
    <phone>650-624-6900</phone>
    <email>pagron@its.jnj.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>#125_Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Robert Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#144_University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Cook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#106_Cedars-Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jaime Moriguchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#154_University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Eric Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#110_Sutter Heart Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>John Chin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#132_University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Munir Janmohamed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#123_MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>David Majure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#126_Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Scott Silvestry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#135_University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Valluvan Jeevanandam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#113_Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Antone Tatooles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#108_Indiana University Health Physicians Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Marco Caccamo, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#112_St. Vincent Medical Group, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Ashwin Ravichandran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#120_University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Cotarlan-Nistor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#152_University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Maya Guglin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#117_University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Emma Birks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#105_Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Stacy Mandra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#129_John Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Ryan Tedford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#143_Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Amanda Vest, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#138_Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Greg Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#119_Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Michael Givertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#115_Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>#102_Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US Med Info US Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Robert Frantz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#150_Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Mark Everley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#104_Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Shane LaRue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#131_University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Zolty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#133_Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Ulrich Jorde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#103_Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Evelyn Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#139_Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Raymond Bietry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#147_Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Gregg Lanier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#148_University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jean Elwing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#153_Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Miriam Jacob, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#101_The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Veronica Franco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#145_The University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Mark Bonnell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#121_Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Doug Horstmanshof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#142_Penn State Heart and Vascular Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>David Silber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#140_Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jeremy Mazurek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#134_Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Richard Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#130_University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jeffery Teuteberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Brian Houston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#141_Palmetto Health / Palmetto Heart</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J McCann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#151_Stern Cardiovascular Foundation</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jawwad Yusuf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#146_Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Mary Keebler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#149_Seton Heart Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Ernest Haeusslein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#136_Baylor Health - Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Shelley Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#107_Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Myung Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#122_Advanced Heart Failure Clinic - HCM</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Chandra Kunavarapu, VM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#127_The University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Edward Gilbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#114_University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Jamie Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#111_Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Shashank Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#116_Virginia Commonwealth University (VCU) Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Smallfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>#155_University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Med Info</last_name>
      <email>usmedinfo@actelion.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Dhingra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LVAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

